Data suggests Lilly’s solanezumab slows progression of mild Alzheimer’s
22 July 2015 | By Victoria White
Lilly has announced results suggesting that solanezumab slows the progression of Alzheimer's in patients with mild disease...
List view / Grid view
News
Novavax announces positive top-line data from Phase 1 Ebola vaccine trial
22 July 2015 | By Victoria White
Novavax has announced positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein recombinant nanoparticle vaccine candidate...
Phase III study of selumetinib in uveal melanoma fails to meet primary endpoint
22 July 2015 | By Victoria White
A Phase III study of selumetinib in combination with dacarbazine for the treatment of metastatic uveal melanoma failed to meet its primary endpoint...
HIV-1 maturation inhibitor BMS-955176 demonstrates positive new Phase IIa results
22 July 2015 | By Victoria White
Bristol-Myers Squibb has announced additional Phase IIa data for BMS-955176, a novel investigational agent designed to prevent the maturation of HIV-1...
NICE gives green light to two eye treatments for treating diabetic macular oedema
22 July 2015 | By Victoria White
NICE has recommended aflibercept solution for injection and dexamethasone implant as treatment options for some people with diabetic macular oedema...
NICE recommends Tegaderm CHG dressing to reduce catheter infections
22 July 2015 | By Victoria White
NICE has recommended the use of 3M Tegaderm CHG IV securement dressing to hold catheters in place securely, reducing the risk of catheter related infections...
BioMarin provides programme update for talazoparib in metastatic breast cancer
21 July 2015 | By Victoria White
BioMarin has provided an update on the ABRAZO Phase 2 study of its poly ADP-ribose polymerase (PARP) inhibitor, talazoparib...
FDA grants Breakthrough Therapy Designation to Bristol-Myers Squibb’s BMS-663068
21 July 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation to BMS-663068 for the treatment of HIV-1 infection in heavily treatment-experienced adult patients...
Tekmira to change company name; suspends development of ebola drug
21 July 2015 | By Victoria White
Tekmira Pharmaceuticals Corporation has announced plans to change its corporate name to Arbutus Biopharma Corporation, to be effective by 3 August 2015...
EC approves Amgen’s cholesterol-lowering medication Repatha
21 July 2015 | By Victoria White
The EC has granted marketing authorisation for Repatha for the treatment of patients with uncontrolled cholesterol who require additional LDL-C reduction...
HerpV and GEN-003 will drive genital herpes treatment market growth to 2023
21 July 2015 | By Victoria White
The global market value for genital herpes therapeutics will increase from approximately $490 million in 2013 to just under $668 million by 2023, largely driven by the introduction of therapeutic vaccines, HerpV and GEN-003, towards the end of the forecast period, says research and consulting firm GlobalData.
Biotie announces start of tozadenant Phase 3 study in Parkinson’s disease
21 July 2015 | By Victoria White
A Phase 3 study of tozadenant in patients with Parkinson's disease experiencing levodopa related end-of-dose "wearing-off" has started...
Phase I clinical trial of oral formulation of MGB-BP-3 for treatment of Clostridium Difficile infections begins
21 July 2015 | By Victoria White
The first group of healthy volunteers have been dosed in a Phase I clinical trial assessing the safety and tolerability of an oral formulation of MGB-BP-3...
EC approves nivolumab for patients with previously-treated advanced squamous non-small cell lung cancer
21 July 2015 | By Victoria White
The EC has approved nivolumab for the treatment of locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy...
Researchers beat untreatable eczema with arthritis drug
20 July 2015 | By Victoria White
Researchers have successfully treated patients with moderate to severe eczema using an arthritis drug recently shown to reverse two other skin conditions...
